10-K · March 5, 2026
Contineum is a clinical-stage biopharma focused on small-molecule NI&I therapies. Key positives: PIPE-791 advanced into a 26-week Phase 2 (PROPEL‑IPF) in December 2025 with ~324 subjects after positive Phase 1b PET data…
Earnings analysis · 10-Q
CTNM earnings analysis
Filed May 5, 2026 · Our reading of the company's report
The latest report
Contineum Therapeutics reported a net loss of $14.5 million for Q1 2026, an improvement from $16.0 million in Q1 2025, primarily due to reduced R&D expenses which fell by 15%. Despite no revenue from product sales, the…
Read full summary
Contineum Therapeutics reported a net loss of $14.5 million for Q1 2026, an improvement from $16.0 million in Q1 2025, primarily due to reduced R&D expenses which fell by 15%. Despite no revenue from product sales, the company maintains a strong cash position of $246.3 million, sufficient to support operations through mid-2029.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.54
What stood out
-
Net Loss Improvement
Net loss decreased to $14.5 million in Q1 2026 from $16.0 million in Q1 2025, a $1.5 million improvement.
-
R&D Expenses Decrease
R&D expenses decreased by 15% to $11.6 million in Q1 2026 from $13.7 million in Q1 2025.
-
Strong Cash Position
Cash, cash equivalents, and marketable securities totalled $246.3 million as of March 31, 2026.
-
R&D Costs Breakdown
Direct external development costs for PIPE-791 were $6.05 million compared to $5.55 million in Q1 2025.
-
Interest Income Increase
Interest income increased to $2.5 million in Q1 2026 from $2.3 million in Q1 2025.
-
Improved Operating Loss
Loss from operations improved to $16.9 million in Q1 2026, compared to $18.1 million in Q1 2025.
What to watch
-
Ongoing Financial Losses
The company continues to operate at a net loss of $14.5 million for Q1 2026.
-
Dependency on Drug Candidates
Future success is heavily reliant on the clinical development of drug candidates like PIPE-791 and PIPE-307.
-
Increased Operating Expenses Expected
Operating expenses are expected to rise as the company scales its clinical trial activities.
Management's outlook
No numeric guidance for revenue or EPS was provided.
Earlier filings 4
10-Q · October 30, 2025
Contineum reported a three-month net loss of $12,792,000 (EPS -$0.45) for the quarter ended September 30, 2025, with operating expenses rising to $14,932,000 from $12,974,000 a year ago. Liquidity remains strong: cash…
10-Q · August 5, 2025
Contineum reported a Q2 net loss of $(16,040) (three months ended June 30, 2025) and EPS of $(0.62), wider than prior-year Q2 EPS of $(0.39). Operating expenses rose to $17,902 (three months) driven by higher R&D of…
10-Q · May 14, 2025
Contineum reported no product revenue and a larger operating cost base in Q1 2025, driving a net loss of $(15,990) (as reported) and GAAP EPS of $(0.62). R&D spend rose materially to $13,712 versus $7,778 in Q1 2024,…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.